Managing type 2 diabetes during COVID-19: 39 million people living with diabetes in MENA
40% COVID-19 deaths in Kuwait, UAE had diabetes
KUWAIT: Boehringer Ingelheim - one of the world’s leading pharmaceutical companies - held a regional media webinar titled ‘Managing type 2 diabetes during COVID-19’ with the participation of leading healthcare professionals who provided the latest updates on type 2 diabetes (T2D) management during the pandemic. The regional media event formed part of the ‘Regional Interchange on Diabetes’ (e-RID) internationally-accredited digital program, organized by Boehringer Ingelheim, targeting more than 5,000 international and regional healthcare professionals in the Middle East, Turkey and Africa region. By hosting prominent international experts from the US, Canada and UK, the scientific program aims at exchanging experiences and practices in managing type 2 diabetes and its complications during COVID-19.
Thirty-nine million people are currently living with diabetes in the Middle East and North Africa, and it is estimated that by 2045, around 82 million people will have the condition, according to the International Diabetes Federation. With diabetes being reported as a risk factor for the severity of COVID19, patients are being encouraged to take precautions to avoid contracting the virus, such as washing hands thoroughly and regularly, cleaning and disinfecting objects and surfaces that are touched frequently, and avoiding contact with anyone showing symptoms of respiratory illness, such as coughing. Patients living with T2D need to pay extra attention to their glucose levels and monitor them regularly to avoid complications caused by high or low blood glucose levels. Should they display flu-like symptoms, it is vital they consult with a physician immediately for medical support.
“At a time where the world is focused on COVID-19, it is crucial to highlight the diseases affecting the lives of so many patients in our region such as Type 2 Diabetes. We felt committed to providing patients living with T2D, their caregivers and the wider healthcare community credible sources of information related to diabetes management and necessary precautions during the pandemic,” said Mohammed Al-Tawil, Regional Managing Director and Head of Human Pharma at Boehringer Ingelheim.
40 percent
“People with diabetes and related comorbidities are at a higher risk of complications from COVID-19. In fact, 40 percent of COVID-19 mortality cases in the UAE and Kuwait as announced had diabetes. It is therefore imperative that we educate patients on diabetes self-management and comorbidities at this time,” explained Dr Mohammed Hassanein, Senior Consultant in Endocrinology and Diabetes at Dubai Hospital. “Patients living with uncontrolled T2D face a higher risk of contracting the virus than patients living with controlled T2D. Our priority is therefore to ensure effective type 2 diabetes control at this critical time.”
Dr Thamer Alessa, Consultant Endocrinologist and Head of the Endocrinology, Diabetes and Metabolism Division at Jaber Al-Ahmad Hospital, Kuwait highlighted the availability of numerous new treatments and medical solutions in the Middle East to support patients living with T2D. “It is important that we bring awareness to the latest updates available. SGLT2 inhibitors and GLP-1 agonists have shown beneficial effects for patients with type 2 diabetes and high cardiovascular and renal impairment risk. These options have proven to help in terms of reducing cardiovascular diseases risk and also chronic kidney disease risk.”
Cardiovascular disease (CVD) remains the number one killer of people with type 2 diabetes, accounting for around 52 percent of type 2 diabetes patients worldwide. Diabetes is a known risk factor for CVD, so are conditions such as high blood pressure and obesity, all commonly seen in people with diabetes. Collectively, this means that the risk of death due to CVD is up to four times higher in people diagnosed with T2D.
Reducing cardiovascular risk is an essential component of diabetes management, therefore patients are encouraged to educate themselves on how to modify cardiovascular risk factors in order to benefit from the best chance at improving their CVD outcomes. A patient-centric and holistic approach are needed to guide the choice of pharmacologic agents used in patients diagnosed with T2D due to the chronic nature of the disease. Considerations include efficacy, hypoglycemia risk, history of CVD, impact on weight, potential side effects, renal effects, delivery method, cost, and patient preferences.
Leading endocrinologists
The ‘Managing type 2 diabetes during COVID19’ webinar session was delivered by leading endocrinologists from the Middle East; Professor Dr Yehia Ghanem, Professor of Diabetes, Lipid and Metabolism, and member of the Egyptian Diabetes National Committee in Egypt, Dr Eman Sheshah, Director of Endocrine and Diabetes Center in King Salman Hospital Riyadh in Saudi Arabia and Dr Paola Atallah, Specialist Endocrinologist at Saint George Hospital University Medical Center in Lebanon.
In April 2020, Boehringer Ingelheim launched its Global Support Program to step up its efforts in support of the fight against COVID-19 in the region. The program focuses on four areas: financial and in-kind donations for local emergency aid worth seven million euros, research for COVID-19 therapies through a team of over 100 highly engaged scientists from all areas of research and development, volunteering to bring COVID-19 relief and supporting social entrepreneurs through the ‘Making More Health’ relief fund.
“Our offices in the Middle East, Turkey and Africa have joined hands to bring financial relief, protective materials and donations of medicine to healthcare institutions and communities in need. So far, we have allocated funds and provided inkind donations for local emergency aid in Jordan, Turkey, Morocco and Tunisia. We are currently gearing up to provide similar support in other countries, including Lebanon, Egypt and Algeria, where it is also much needed,” Tawil added.
82 million to have diabetes by 2045